当前位置: 首页 >> 检索结果
2321. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
作者: Fred Poordad.;William Sievert.;Lindsay Mollison.;Michael Bennett.;Edmund Tse.;Norbert Bräu.;James Levin.;Thomas Sepe.;Samuel S Lee.;Peter Angus.;Brian Conway.;Stanislas Pol.;Nathalie Boyer.;Jean-Pierre Bronowicki.;Ira Jacobson.;Andrew J Muir.;K Rajender Reddy.;Edward Tam.;Grisell Ortiz-Lasanta.;Victor de Lédinghen.;Mark Sulkowski.;Navdeep Boparai.;Fiona McPhee.;Eric Hughes.;E Scott Swenson.;Philip D Yin.; .
来源: JAMA. 2015年313卷17期1728-35页
The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection.
2322. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
作者: Dale N Gerding.;Thomas Meyer.;Christine Lee.;Stuart H Cohen.;Uma K Murthy.;Andre Poirier.;Trevor C Van Schooneveld.;Darrell S Pardi.;Antonio Ramos.;Michelle A Barron.;Hongzi Chen.;Stephen Villano.
来源: JAMA. 2015年313卷17期1719-27页
Clostridium difficile is the most common cause of health care-associated infection in US hospitals. Recurrence occurs in 25% to 30% of patients.
2329. Association of Pioneer Accountable Care Organizations vs traditional Medicare fee for service with spending, utilization, and patient experience.
作者: David J Nyweide.;Woolton Lee.;Timothy T Cuerdon.;Hoangmai H Pham.;Megan Cox.;Rahul Rajkumar.;Patrick H Conway.
来源: JAMA. 2015年313卷21期2152-61页
The Pioneer Accountable Care Organization (ACO) Model aims to drive health care organizations to reduce expenditures while improving quality for fee-for-service (FFS) Medicare beneficiaries.
|